Bile Duct Neoplasms Market: Industry trends, Drugs, Companies and Analysis | Agios Pharmaceuticals, Incyte Corporation, Delcath Systems, QED Therapeutics, Nucana and Others

Bile Duct Neoplasms Market: Industry trends, Drugs, Companies and Analysis | Agios Pharmaceuticals, Incyte Corporation, Delcath Systems, QED Therapeutics, Nucana and Others

“Bile Duct Neoplasms Market”

Bile Duct Neoplasms also known as Biliary Tract Cancer is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation.

The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gallbladder. Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.

Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.

DelveInsight’s “Bile Duct Neoplasms Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Bile Duct Neoplasms, historical and forecasted epidemiology as well as the Bile Duct Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of the Bile Duct Neoplasms Facts:

  • Among the EU5 countries, Germany had the highest incident population of Bile Duct Neoplasms with 4,471 cases, followed by Italy and the United Kingdom.
  • As per DelveInsight insights, the incidence rate varied based on type specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.
  • DelveInsight’s assessment based on the recent studies suggests that overall 37% of the CCA cases belongs to US in the 7M for the study period of 2017.
  • Spain had the lowest incident population. As per our estimates, Japan had 4,287 incident cases of Bile Duct Neoplasms in 2017.


Request for free Sample Report:


Scope of the Bile Duct Neoplasms Report:

  • Bile Duct Neoplasms market report provides an in-depth analysis of Bile Duct Neoplasms Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Bile Duct Neoplasms market report will help in developing business strategies by understanding the Bile Duct Neoplasms Market trends & developments, key players and future market competition that will shape and drive the Bile Duct Neoplasms market in the upcoming years.
  • The Bile Duct Neoplasms market report covers Bile Duct Neoplasms current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Bile Duct Neoplasms market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Key Bile Duct Neoplasms companies Covered:

  • Agios Pharmaceuticals
  • Incyte Corporation
  • Delcath Systems
  • QED Therapeutics
  • Nucana
  • And Many Others


Request for free Sample Report:


Bile Duct Neoplasms Drugs Covered:

  • Ivosidenib
  • Pemigatinib
  • Melphalan Hydrochloride
  • Infigratinib
  • Acelarin
  • And Many Others


Request for free Sample Report:


Table of Contents:

1. Key Insights

2. Executive Summary of Bile Duct Neoplasms

3. Competitive Intelligence Analysis for Bile Duct Neoplasms

4. Bile Duct Neoplasms: Market Overview at a Glance

5. Bile Duct Neoplasms: Disease Background and Overview

6. Patient Journey

7. Bile Duct Neoplasms Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Bile Duct Neoplasms Treatment

11. Marketed Products

12. Emerging Therapies

13. Bile Duct Neoplasms: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Bile Duct Neoplasms

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC:


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States